US Patent

US8344006 — Liquid formulations of bendamustine

Method of Use · Assigned to Cephalon LLC · Expires 2029-09-23 · 3y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable liquid formulations of bendamustine and its pharmaceutically acceptable salts.

USPTO Abstract

Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1402`	—	bendamustine-hydrochloride
`U-1402`	—	bendamustine-hydrochloride

Patent Metadata

Patent number: US8344006
Jurisdiction: US
Classification: Method of Use
Expires: 2029-09-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Cephalon LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.